Diabetes affects more than nine million Mexicans to control the problem and need to move towards a solution with coordinated between government, industry and society efforts, said President and CEO of Eli Lilly Mexico, Carlos Baños.
Boehringer Ingelheim and Eli Lilly & Company celebrated the third anniversary of their alliance with the approval of its inhibitor SGTL2 by the Federal Commission for Protection against Health Risks (COFEPRIS).
This medication is added to the treatment alternatives that exist in the market and seek to initiate the process to make it available to patients in health institutions and basic frame, to the president of Eli Lilly Mexico, Carlos Baños.
Meanwhile, the president and CEO of Boehringer Ingelheim Mexico and Central America, Miguel Salazar, explains that since the birth of the alliance in 2001 invested more than 20 percent of its sales in research and development.
He explained that the alliance combines solid history of the firm that presides in innovation, plus the experience of Eli Lilly as a pioneer in diabetes and the development of both the first human insulin as the first insulin analogue in the world.
In turn, the management of Eli Lilly said the magnitude, frequency, growth and pressure exerted on the National Health System, became T2DM diabetes along with obesity and heart disease, the most expensive and main enemy to defeat.
In Mexico the annual expense of complications arising from the disease more than seven billion pesos in 2011, the health costs arising from the same internationally amounted to 465 billion dollars, which means 11 percent of the resources Total global health sector.
0 comments:
Post a Comment